Modular Medical, Inc. (NASDAQ: MODD) priced a public offering of 68,098,000 shares of common stock (or pre‑funded warrants) at $0.1762 per share on March 3, 2026. The offering also includes warrants to purchase up to an additional 68,098,000 shares, giving the company a total potential issuance of 136,196,000 shares. The gross proceeds are expected to be approximately $12 million before underwriting and other fees.
The proceeds will be used to support the company’s upcoming Pivot insulin‑delivery system launch and to shore up its cash position amid a high burn rate. The Pivot pump is not yet FDA‑cleared; its commercial launch in Q1 2026 is contingent on 510(k) clearance. The company’s prior financials underscore the urgency of the raise: in Q1 2025 it reported a net loss of $4.14 million on operating expenses of $4.22 million, and for the nine months ended December 31 2025 it posted a net loss of $21.85 million, driven by $16.13 million in R&D and $5.75 million in SG&A expenses.
The offering represents a substantial dilution relative to the company’s market capitalization. At the time of pricing, Modular Medical’s market cap was roughly $9.57 million, meaning the $12 million raise exceeds the market value of the existing equity. This level of dilution signals the company’s need for additional capital to reach a commercial launch and to maintain operations in a pre‑revenue, high‑burn environment.
CEO Jeb Besser emphasized the strategic importance of the Pivot line, stating, "Validating the Pivot controller line further evidences our ability to scale production efficiently, which is a key differentiator in the patch pump space. We remain on track for a Q1 2026 market launch, as we look to introduce our Pivot product to millions of patients who deserve better diabetes management options." The statement highlights the company’s confidence in its manufacturing milestones while acknowledging the financial challenges that necessitate the capital raise.
The offering’s timing and size reflect Modular Medical’s ongoing effort to secure the resources needed to transition from a development‑stage company to a commercial player in the insulin pump market. The high burn rate, lack of revenue, and pending regulatory approval underscore the fragility of the business, making the capital raise a critical, material event for investors and stakeholders.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.